Protein p53

Related Subjects: |Polymerase chain reaction |Insulin Physiology |Protein p53

p53 ("guardian of the genome") is the most important tumor suppressor protein, encoded by TP53 (chromosome 17p13.1). It responds to stress (DNA damage, oncogene activation, hypoxia) by inducing cell cycle arrest, DNA repair, apoptosis, senescence, and metabolic reprogramming to prevent cancer. Mutated in ~50% of human cancers (hotspots in DBD); germline mutations cause Li-Fraumeni syndrome. 2025–2026 advances: mutant p53 GOF in TME/immune evasion, rezatapopt (Y220C reactivator) phase 1/2 success, dPCR for MRD.

🧬 Structure of p53 Protein

Human p53: 393 amino acids; forms functional tetramer (dimer-of-dimers).

⚙️ Key Functions of p53

• Cell Cycle Arrest 🛑: Activates p21 (CDKN1A) → G1/S & G2/M checkpoints; allows DNA repair.
• DNA Repair 🔧: Upregulates GADD45, DDB2, XPC (nucleotide excision repair); TIGAR (metabolic shift to repair).
• Apoptosis 💀: Intrinsic (BAX/BAK/PUMA/NOXA → mitochondrial outer membrane permeabilization); extrinsic (FAS/DR5).
• Senescence ⏳: Permanent arrest via p21, PAI-1, IGFBP7; prevents proliferation of damaged cells.
• Other (2025–2026 insights):
  • Metabolic reprogramming: Inhibits glycolysis (TIGAR), promotes OXPHOS.
  • Autophagy/ferroptosis/cuproptosis/pyroptosis: Context-dependent regulation.
  • Tumor microenvironment: Suppresses angiogenesis, inflammation; mutant p53 promotes immune evasion/stemness.
  • m6A modification links: Influences RNA methylation in cancer progression.

🛡️ Regulation of p53 Activity

• MDM2/MDMX negative feedback: MDM2 E3 ligase ubiquitinates p53 → proteasomal degradation; MDMX inhibits transactivation. Stress disrupts MDM2–p53 binding.
• Post-translational modifications (PTMs): Phosphorylation (Ser15/20/46 by ATM/ATR/DNA-PK), acetylation (Lys382 by p300/CBP), methylation (Lys370/372), SUMOylation → stabilization, tetramerisation, DNA binding, nuclear retention.
• Stabilisation under stress: DNA damage → ATM/ATR/Chk1/2 → p53 phosphorylation → ↓ MDM2 binding → accumulation & activation.

🩺 Role of p53 in Cancer

• TP53 mutations: ~50% all cancers (missense in DBD hotspots: R175H, R248Q, R273H); loss-of-function (LOF) + dominant-negative (DNE) + gain-of-function (GOF: TME remodelling, chemoresistance, stemness).
• Mutant p53 GOF (2025–2026): Binds new partners (e.g., p63/p73 inhibition), alters chromatin, promotes invasion/metastasis, immune evasion.
• Therapeutic implications: Mutant reactivation (rezatapopt for Y220C → phase 1/2: ~20% response in advanced solids, 2025–2026 NEJM); MDM2 inhibitors (e.g., idasanutlin); mutant degradation; secondary TP53 mutations cause resistance.

🧬 Clinical Relevance

• Li-Fraumeni Syndrome (LFS): Germline TP53 pathogenic variants → autosomal dominant; lifetime cancer risk ~90% (women > men); ~50% by age 40; core cancers: breast, sarcoma, brain, adrenocortical, leukaemia; screening protocols (whole-body MRI, breast MRI, etc.). Prevalence ~1:20,000 (higher with panels).
• Sporadic cancers: TP53 status prognostic (mutant worse); predicts chemo/radio response (wild-type more sensitive).
• Therapeutic strategies (2026):
  • Reactivators: Rezatapopt (Y220C-specific; promising ovarian/solid tumors).
  • MDM2 antagonists/degraders (e.g., PROTACs).
  • Gene therapy: Adenoviral wild-type TP53 (limited efficacy).
  • Combination: With immunotherapy (mutant p53 immunogenicity).

Teaching Point 🩺: p53 guards the genome via arrest, repair, apoptosis, senescence. Stress → PTMs → stabilisation → target gene activation (p21, BAX, etc.). Mutated in ~50% cancers → LOF/DNE/GOF. LFS: germline TP53 → high multi-cancer risk. Emerging therapies: mutant reactivators (e.g., rezatapopt), MDM2 inhibitors; resistance via secondary mutations.

📚 References (Feb 2026)

• Wang H et al. Targeting p53 pathways. Signal Transduct Target Ther 2023 (updated reviews 2025).
• Grigoreva TA et al. p53 covalent modifications in cancer. Pharmaceuticals 2024.
• NEJM: Rezatapopt phase 1/2 (2025–2026).
• Cancer Discovery: Resistance mechanisms (Jan 2026).
• NCCN/Facing Our Risk: LFS cancer risks (2025–2026).